BR112013031354A2 - "Method of profiling a sample of an individual for dengue hemorrhagic fever, method of identifying an individual at risk for dengue hemorrhagic fever and kit for identifying an individual infected with dengue virus" - Google Patents

"Method of profiling a sample of an individual for dengue hemorrhagic fever, method of identifying an individual at risk for dengue hemorrhagic fever and kit for identifying an individual infected with dengue virus"

Info

Publication number
BR112013031354A2
BR112013031354A2 BR112013031354A BR112013031354A BR112013031354A2 BR 112013031354 A2 BR112013031354 A2 BR 112013031354A2 BR 112013031354 A BR112013031354 A BR 112013031354A BR 112013031354 A BR112013031354 A BR 112013031354A BR 112013031354 A2 BR112013031354 A2 BR 112013031354A2
Authority
BR
Brazil
Prior art keywords
individual
hemorrhagic fever
identifying
risk
dengue
Prior art date
Application number
BR112013031354A
Other languages
Portuguese (pt)
Inventor
Adrian Recinos
Allan Brasier
Eduardo Nascimento
Ernesto E T Marques
Heidi Spratt
Hyunsu Ju
John E Wiktorowicz
Laura H V G Gil
Marli Tenorio
Nikos Vasilakis
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112013031354A2 publication Critical patent/BR112013031354A2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)

Abstract

method and biomarkers for the detection of dengue hemorrhagic fever abstract the present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules used to diagnose patient with risk of dhf. more particularly, the invention provides plasma biomarkers including complement factor d to complement factor h (factord/factorh) ratio and levels of one or more of il2, desmoplakin, and high molecular weight albumin, which are used to detect risk of developing dhf. tradução do resumo resumo patente de invenção: "método e biomarcadores para a detecção da febre hemorrágica da dengue". a presente invenção apresenta composições e métodos para a detecção, análise e identificação de biomoléculas usadas para diagnosticar pacientes com risco de dhf. mais particularmente, a invenção apresenta biomarcadores plasmáticos, incluindo a razão de fator de complemento d para fator de complemento h (fatord/fatorh) e níveis de uma ou mais de il2, desmoplaquina e albumina de alto peso molecular, que são usados para detectar o risco de desenvolver dhf.method and biomarkers for the detection of dengue hemorrhagic fever abstract the present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules used to diagnose patient with risk of dhf. more particularly, the invention provides plasma biomarkers including complement factor d to complement factor h (factord / factorh) ratio and levels of one or more of il2, desmoplakin, and high molecular weight albumin, which are used to detect risk of developing dhf. abstract method and biomarkers for the detection of dengue hemorrhagic fever. The present invention provides compositions and methods for detecting, analyzing and identifying biomolecules used to diagnose patients at risk of dhf. more particularly, the invention features plasma biomarkers, including the ratio of complement factor d to complement factor h (fatord / factorh) and levels of one or more high molecular weight il2, desmoplazine and albumin, which are used to detect the risk of developing dhf.

BR112013031354A 2011-06-06 2012-06-06 "Method of profiling a sample of an individual for dengue hemorrhagic fever, method of identifying an individual at risk for dengue hemorrhagic fever and kit for identifying an individual infected with dengue virus" BR112013031354A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493923P 2011-06-06 2011-06-06
PCT/US2012/041131 WO2012170556A1 (en) 2011-06-06 2012-06-06 Method and biomarkers for the detection of dengue hemorrhagic fever

Publications (1)

Publication Number Publication Date
BR112013031354A2 true BR112013031354A2 (en) 2016-09-13

Family

ID=47296417

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031354A BR112013031354A2 (en) 2011-06-06 2012-06-06 "Method of profiling a sample of an individual for dengue hemorrhagic fever, method of identifying an individual at risk for dengue hemorrhagic fever and kit for identifying an individual infected with dengue virus"

Country Status (3)

Country Link
US (3) US10168337B2 (en)
BR (1) BR112013031354A2 (en)
WO (1) WO2012170556A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10168337B2 (en) 2011-06-06 2019-01-01 The Board Of Regents Of The University Of Texas System Method and biomarkers for the detection of dengue hemorrhagic fever
WO2014081974A1 (en) * 2012-11-21 2014-05-30 Massachusetts Institute Of Technology Biomarkers for dengue fever and use thereof
DE102013011495A1 (en) * 2013-07-02 2015-01-08 Laser- Und Medizin-Technologie Gmbh, Berlin Method for determining the concentration of a substance in a deformable container
DE102014107380A1 (en) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät A method of diagnosing a disease mediated by the alternative pathway of the complement system or a risk therefor
JP2022523564A (en) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド Data compression and communication using machine learning
CN113345525B (en) * 2021-06-03 2022-08-09 谱天（天津）生物科技有限公司 Analysis method for reducing influence of covariates on detection result in high-throughput detection
WO2023114779A1 (en) * 2021-12-14 2023-06-22 Evidation Health, Inc. Systems and methods for predicting, detecting, and monitoring of acute illness

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2347039A4 (en) 2008-10-14 2012-08-01 Univ Mcgill Biomarkers for dengue
US20130236917A1 (en) * 2010-11-12 2013-09-12 The Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
US10168337B2 (en) 2011-06-06 2019-01-01 The Board Of Regents Of The University Of Texas System Method and biomarkers for the detection of dengue hemorrhagic fever

Also Published As

Publication number Publication date
US20160003845A1 (en) 2016-01-07
US20130004473A1 (en) 2013-01-03
US9103826B2 (en) 2015-08-11
US10168337B2 (en) 2019-01-01
WO2012170556A1 (en) 2012-12-13
US10126309B2 (en) 2018-11-13
US20150316562A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
BR112013031354A2 (en) "Method of profiling a sample of an individual for dengue hemorrhagic fever, method of identifying an individual at risk for dengue hemorrhagic fever and kit for identifying an individual infected with dengue virus"
Prabhu et al. Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth
CY1121872T1 (en) EVALUATION, TESTING AND TREATMENT OF PKAL-MEDIATED DISORDERS
BR112018072627A2 (en) performing optical measurements on a sample
BR112014011491A2 (en) trials and methods for selecting a treatment regimen for an individual with depression
BR112014016313A8 (en) Accurate analyte measurements for electrochemical test strip based on detected physical characteristic (s) of sample containing analyte and derived biosensor parameters
BRPI1007867B8 (en) recombinant antibody or antigen-binding fragment thereof, pharmaceutical composition and kit comprising said antibody, methods of detecting troponin i antigen in a test sample, and in vitro methods of diagnosing acute coronary syndrome or myocardial infarction in a patient
BR112014010718A2 (en) methods and systems for sample analyte detection
BR122018069446B8 (en) in vitro method to detect the presence of a cancer cell in an individual
BRPI1013532A2 (en) cuvette spectrometer
Yang et al. Peptidome analysis reveals novel serum biomarkers for children with autism spectrum disorder in China
WO2015006160A3 (en) Biomarkers of autism spectrum disorder
Li et al. Peripheral blood mononuclear cell-based metabolomic profiling of a chronic unpredictable mild stress rat model of depression
UY30893A1 (en) METHODS AND DEVICES FOR THE APPENDICITIS DIAGNOSIS
BR112021024111A2 (en) Determination of antidepressants by mass spectrometry
BR112013022910A2 (en) process and device for testing the ability to function properly of an elevator
BR112013005442A2 (en) analyte measurement method and hematocrit compensation system
BR112018067435A2 (en) mass spectrometry kit
BR112014005651A2 (en) diagnostic apparatus
BR112015008036A2 (en) isolated peptide population, method for detecting antibody in a sample, method for diagnosing monocytic and / or granulocytic erlichiosis, and kit
ATE522814T1 (en) DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY AND LUNG USING PROVASOPRESSIN, IN PARTICULAR COPEPTIN OR NEUROPHYSIN II
BR112021021835A2 (en) Method for measuring the concentration of a gaseous substance in an environment using a gas sensor, method of calibrating a gas sensor and gas sensor apparatus
BR112018069316A2 (en) methods for detecting the presence of at least one pathogenic bordetella species and selecting a patient exhibiting pertussis-like symptoms, and kit for detecting the presence of at least one pathogenic bordetella species.
BR112015010399A2 (en) Method and kit for the determination of serum free copper
HK1136873A1 (en) Use of nnmt as a marker for lung cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained